QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:COGT

Cogent Biosciences (COGT) Stock Price, News & Analysis

$7.34
-0.15 (-2.00%)
(As of 02/28/2024 ET)
Today's Range
$7.13
$7.57
50-Day Range
$4.38
$9.02
52-Week Range
$3.67
$13.51
Volume
2.17 million shs
Average Volume
2.45 million shs
Market Capitalization
$632.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.43

Cogent Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
110.2% Upside
$15.43 Price Target
Short Interest
Bearish
7.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Cogent Biosciences in the last 14 days
Based on 34 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.95) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

Medical Sector

522nd out of 959 stocks

Pharmaceutical Preparations Industry

239th out of 437 stocks


COGT stock logo

About Cogent Biosciences Stock (NASDAQ:COGT)

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

COGT Stock Price History

COGT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Baird Downgrades Cogent Biosciences (COGT)
Cogent Biosciences GAAP EPS of -$0.63
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.6%
See More Headlines
Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
2/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COGT
Fax
N/A
Employees
138
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.43
High Stock Price Target
$26.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+108.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
8 Analysts

Profitability

Net Income
$-140,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.72 per share

Miscellaneous

Free Float
81,732,000
Market Cap
$638.15 million
Optionable
Optionable
Beta
1.39
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Andrew R. Robbins M.B.A. (Age 48)
    President, CEO & Director
    Comp: $981.4k
  • Dr. John Edward Robinson Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $633.73k
  • Dr. Jessica Sachs M.D. (Age 49)
    Chief Medical Officer
    Comp: $672.5k
  • Mr. John L. Green C.A.Mr. John L. Green C.A. (Age 44)
    CPA, CFO & Principal Accounting Officer
    Comp: $763.99k
  • Mr. Brad Barnett
    Chief Technology Officer
  • Christi Waarich
    Senior Director of Investor Relations
  • Mr. Evan D. Kearns J.D. (Age 44)
    Chief Legal Officer & Corporate Secretary
  • Ms. Erin Schellhammer
    Chief People Officer
  • Mr. Dana R. Martin Pharm.D.
    Senior Vice President of Medical Affairs
  • Brad Fell
    Senior Vice President of Chemistry














COGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cogent Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COGT shares.
View COGT analyst ratings
or view top-rated stocks.

What is Cogent Biosciences' stock price target for 2024?

8 Wall Street analysts have issued 12-month price targets for Cogent Biosciences' stock. Their COGT share price targets range from $8.00 to $26.00. On average, they predict the company's stock price to reach $15.43 in the next twelve months. This suggests a possible upside of 110.2% from the stock's current price.
View analysts price targets for COGT
or view top-rated stocks among Wall Street analysts.

How have COGT shares performed in 2024?

Cogent Biosciences' stock was trading at $5.88 on January 1st, 2024. Since then, COGT shares have increased by 24.8% and is now trading at $7.34.
View the best growth stocks for 2024 here
.

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a increase in short interest in February. As of February 15th, there was short interest totaling 6,240,000 shares, an increase of 23.8% from the January 31st total of 5,040,000 shares. Based on an average daily trading volume, of 2,510,000 shares, the short-interest ratio is currently 2.5 days.
View Cogent Biosciences' Short Interest
.

When is Cogent Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our COGT earnings forecast
.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) announced its quarterly earnings results on Monday, February, 26th. The technology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08.

What ETF holds Cogent Biosciences' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 8,462 shares of COGT stock, representing 0.90% of its portfolio.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

Who are Cogent Biosciences' major shareholders?

Cogent Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (6.80%), Point72 Asset Management L.P. (6.03%), Vanguard Group Inc. (5.27%), Eventide Asset Management LLC (2.59%), Frazier Life Sciences Management L.P. (2.32%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Fairmount Funds Management Llc and John L Green.
View institutional ownership trends
.

How do I buy shares of Cogent Biosciences?

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COGT) was last updated on 2/28/2024 by MarketBeat.com Staff